What Is ‘Treatment as Prevention?’
Treatment as prevention (or TasP) refers to ways in which we can use HIV drugs, or HIV treatment, to lower the risk of transmitting HIV. For people living with HIV (HIV+), one of the benefits of taking HIV drugs is that the drugs can reduce their viral load (amount of virus in their blood), thus making their blood, vaginal fluids, breast milk, and semen (cum) extremely unlikely to transmit HIV to others. When it comes to HIV transmission through sex, research has shown that when a person living with HIV is taking HIV drugs and their viral load has reached undetectable levels (not enough HIV in their bloodstream for a test to measure), that person cannot transmit HIV to a partner who is HIV-negative. For more information on this exciting development, please see our fact sheet on Undetectable Equals Untransmittable.
Keeping their viral load low also helps people living with HIV feel better. A low viral load means a healthier immune system, which in turn prevents the person from progressing to AIDS and getting other infections.
Preventing Mother-To-Child Transmission (PMTCT)
Treatment as prevention has been in use since the 1990s, when research showed that pregnant women living with HIV who used Retrovir (an HIV drug also called zidovudine or AZT) greatly reduced the risk of transmitting HIV to their babies. It has now become standard practice to test pregnant women for HIV, provide HIV drugs to women living with HIV during pregnancy, delivery, and breastfeeding, and give HIV drugs to the babies of women living with HIV. All of this is referred to as preventing mother-to-child transmission (PMTCT). PMTCT is also known as preventing perinatal or vertical transmission. According to the US Centers for Disease Control and Prevention (CDC), nowadays, if a mother takes HIV drugs while pregnant and has an undetectable viral load, the chances of transmission to her baby are less than one in 100.
Treatment as Prevention in Sexually Active Adults
TasP also increases the possibility that mixed-status couples (couples in which one partner is living with HIV and the other is HIV-negative, also known as serodiscordant or serodifferent couples) who want to have children can safely conceive their babies “the old-fashioned way”: through sex without condoms or other barriers. The HIV-negative partner can also take an HIV medication to prevent him or her from acquiring HIV. This prevention method is called pre-exposure prophylaxis, or PrEP.
In 2011, an important study called HPTN 052, the first “treatment as prevention” study, showed that if the HIV+ member of a serodifferent heterosexual couple took HIV drugs and had an undetectable viral load, they could reduce the chance that their HIV-negative partner would acquire HIV by up to 96 percent. It is important to note that this effect happened when each partner living with HIV took HIV drugs even though they did not have any HIV-related symptoms and their CD4 counts were between 350 and 500 cells/mm3.
In 2016, the PARTNER study showed that after 58,000 instances of sex among 1,166 heterosexual and gay serodifferent couples who were not using condoms, there were zero cases of HIV acquisition within the couples: None from anal or vaginal sex; or to women; or to people living with other sexually transmitted infections (STIs). As noted above, this new development is now called undetectable = untransmittable (U=U).
Treatment with a Public Health Twist
Based on the results of the HPTN 052 study, Michel Sidibé, the Executive Director of UNAIDS, stated that:
“This breakthrough is a serious game-changer and will drive the prevention revolution forward. It makes HIV treatment a new priority prevention option.” (from “Groundbreaking trial results confirm HIV treatment prevents transmission of HIV”)
In fact, the HPTN 052 study changed HIV prevention by adding another tool – treatment – to the prevention toolbox. Here’s how it works, from a public health (rather than individual health) point of view: if a large enough number of people living with HIV could be treated so that their viral loads dropped to an undetectable level, they would be much less likely to transmit HIV — in fact, their chances of transmitting HIV sexually would be almost zero. This would mean that the number of new HIV acquisitions would drop remarkably. In public health or population terms, this is referred to as a drop in the ‘community viral load.’
“Test and treat” strategies depend on math-based models of how treatment as prevention will change the course of the epidemic. These public health models recommend universal HIV testing to identify people living with HIV, followed by immediate treatment of all people living with HIV, which is now also recommended by all HIV treatment guidelines.
In recent years, studies have shown that how well treatment as prevention works can vary, depending on several factors. These include:
- Healthcare systems able to provide testing, linkage to care, and HIV drugs
- Willingness and ability of people to get tested for HIV (HIV-related stigma and discrimination make people less likely to get tested)
- Willingness and ability of people living with HIV to stick to their HIV drug regimens so that their viral load remains undetectable
Unfortunately, the first major research study of this ‘test and treat’ strategy (ANRS 12249) showed that HIV treatment did not reduce new infections in the community. Scientists at the AIDS 2016 conference in South Africa reported that the study was successful in treating more community members, but apparently many of the people newly diagnosed with HIV did not adhere to their HIV treatment, thus making ‘treatment as prevention’ ineffective.
Additional Methods for Preventing HIV Acquisition
While treatment as prevention is often discussed solely in the context of treating people living with HIV, there are also opportunities for treatment to serve as prevention for HIV-negative people.
PrEP (Pre-Exposure Prophylaxis)
PrEP stands for Pre-Exposure Prophylaxis. It means taking medicine before being exposed to something to prevent yourself from getting a disease or condition. In the context of HIV and women, this means that HIV-negative women take HIV drugs to reduce their risk of getting HIV if they are exposed to it. This can be especially helpful when HIV-negative women whose male partners are living with HIV want to get pregnant. Research has shown that PrEP is a promising tool for women to prevent HIV infection without their partners’ cooperation. For more information on PrEP, please see our fact sheet on PrEP for Women.
PEP (Post-Exposure Prophylaxis)
PEP stands for Post-Exposure Prophylaxis. It refers to taking HIV drugs for about a month immediately after possible exposure to HIV (e.g., needle-stick, sexual assault, unprotected sex). For PEP to be effective, it must be taken as soon as possible after exposure to HIV – within the first 72 hours if possible.
Researchers continue to examine the promise of treatment as prevention as a real game-changer to affect the course of the HIV pandemic. A recent study showed that, in serodifferent heterosexual couples, taking PrEP as a ‘bridge’ – the HIV-negative partner takes PrEP while the partner living with HIV takes the first six months of antiretroviral treatment – reduced HIV transmissions by 96 percent. Another study found that an undetectable viral load in the partner living with HIV makes it impossible to transmit the virus to their HIV-negative partner. Treatment as prevention is important because it not only can positively affect the health and well-being of those living with HIV, but also serve to protect those who are HIV-negative.
Select the links below for additional material related to TasP.
[Note from TheBody: This article was originally published by The Well Project on April 3, 2019. We have cross-posted it with their permission.]